NCNA Overview

U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones index dropping over 100 points on Friday, while several companies, including IBEX Limited, saw significant gains after reporting strong financial results.

IBEX Limited's Financial Success: IBEX Limited's shares surged 33.7% to $40.74 after reporting quarterly earnings of 87 cents per share, exceeding analyst expectations, and providing optimistic sales guidance for FY26.

Compliance Notification: NuCana has received formal notification from Nasdaq confirming compliance with all continued listing criteria, including the $1.00 minimum bid price requirement.

Stock Performance: Following the announcement, NuCana's stock (NCNA) rose by 2.44% in premarket trading, reaching a price of $2.93.

NuCana's Presentation at ESMO Congress 2025: NuCana plc will present research on the synergy between NUC-7738 and PD-1 inhibition in renal cell cancer at the ESMO Congress 2025, scheduled for October 17-21 in Berlin, with the presentation set for October 19.

About NuCana's Drug Development: NuCana is focused on enhancing cancer treatment through its ProTide technology, with ongoing clinical studies for its drug candidates NUC-7738 and NUC-3373, aimed at improving efficacy and safety in cancer therapies.

Upcoming Stock Splits: Several companies, including NuCana, Veru, and Energous, are implementing reverse stock splits to comply with Nasdaq's minimum bid price requirements, effective between August 11 and August 15.

Purpose of Stock Splits: Stock splits, whether traditional or reverse, aim to adjust share prices to make stocks more appealing to investors and maintain compliance with exchange listing rules.

Change in ADS Ratio: NuCana plc will change the ratio of its American Depository Shares (ADSs) from 1 ADS representing 25 ordinary shares to 1 ADS representing 5,000 ordinary shares, effective August 11, 2025, which is akin to a one-for-two hundred reverse split but will not affect shareholders' proportional equity interests.

Company Overview: NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, with ongoing studies for its product candidates NUC-7738 and NUC-3373 aimed at enhancing efficacy and safety compared to traditional chemotherapy agents.

WK Kellogg Co Acquisition News: Shares of WK Kellogg Co surged 50.2% in pre-market trading following a Wall Street Journal report that Ferrero is close to acquiring the company for approximately $3 billion, with a deal potentially finalized this week.

Pre-Market Stock Movements: Several stocks experienced significant pre-market trading changes, including Steakholder Foods Ltd rising 137.6% and Mereo BioPharma Group plummeting 36.6%, amidst various corporate developments and earnings reports.